The Bet Behind Genmab's Rally

If you only glanced at Genmab's headlines about rising top-line figures and expanding epcoritamab trials, you might expect a far wilder ride than investors actually experienced. For Genmab shareholders, the return from the start of the year was 21.8%, including dividends. If you were weighing that decision back on 1 January 2026, with bulls talking about precision medicine and bears stressing pricing pressure and patent risk, which part of the story really mattered?

A Narrative on Simply Wall St is one investor's written case for a company, with its growth, margin and multiple assumptions spelled out. Those assumptions imply an estimated Fair Value.

Genmab is not the only name tied to this theme. Zero in on 126 healthcare AI stocks and compare how each one is priced.

The Two Genmab Stories Investors Had To Weigh

Genmab shares cost DKK2,021 at the start, and investors had to choose which story about the future felt more realistic.

The bullish narrative put Fair Value at DKK2,700. It rested on annual revenue growth of 23.7% and an assumption that profit margins would settle at 29.4%, helped by precision medicine trends and an aging population widening biologics demand.

The bearish view argued for Fair Value of DKK1,000. That case focused on reliance on a few oncology products and the risk that tighter drug pricing and higher research costs would constrain margins.

What The Evidence Did To The Genmab Argument

Genmab’s later news flow leaned toward the bullish script, with positive Phase 3 epcoritamab combinations, new approvals in follicular lymphoma and solid efficacy data in elderly DLBCL patients supporting the growth and pipeline depth assumptions behind the higher Fair Value. Reported figures told a cooler story. Revenue rose from US$925m to US$1.155b, while net income slipped and net margin fell from 36.3% to 26.2%. Overall, the evidence cut both ways.

The clear lesson is to test any growth story against profitability and product concentration. When you see a biotech built around a few therapies, watch both margin trends and how many distinct drugs and indications contribute to the top line before trusting an optimistic case.

What Genmab's Gain Leaves You Paying For Today

Genmab now trades at DKK2,445, up from DKK2,021 from the start of the year. The selected Narrative’s Fair Value sits below the current price, so today’s valuation already reflects a confident execution story.

The Narrative focuses on earnings pressure from heavier late stage spending, amortization and tax, rather than sales alone. A buyer today effectively assumes Genmab can convert its late stage assets into durable per share profit. The key question is how that aligns with the risk that additional trial costs and non cash charges limit progress in earnings per share.

"Despite recent guidance increases, first quarter 2026 showed a roughly 73% decline in net income attributable to common shareholders and weaker operating cash flow while revenue grew 25%. This suggests that higher development, acquisition and commercialization spending could continue to dilute the translation of future sales growth into cash and net margins."

Not everyone reads the same price the same way. → See the lower figure this Narrative lands on, and how it gets there

Another Way To Play Genmab

Watching Genmab, you are really watching demand for complex therapies. Cancer, autoimmune conditions, mental health. Problems that rarely have simple treatments.

Those same medical needs support another giant health business. It spreads risk across many treatments instead of relying on a narrow set of drugs.

This group puts capital into new medicines and medical devices. It pushes into hard diseases and advanced surgical tools.

For you, that is a different angle on the same trend. One company leans on focused biologics, the other on breadth and durability.

It is written up in full, assumptions and all. → Explore the Narrative that puts this company 22% above its price

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com